Tanabe Seiyaku Launches New Anti-rheumatic.Tokyo, Japan, July 24, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Tanabe Seiyaku launched Methotrexate methotrexate, drug used in halting the growth of actively proliferating tissues. Introduced in the 1950s, it is used in the treatment of leukemia, psoriasis, and non-Hodgkin's lymphoma. tablets 2mg TANABE (generic name generic name n. 1. The official nonproprietary name of a drug, under which it is licensed and identified by the manufacturer. 2. : methotrexate), an anti-rheumatic drug for the indication of rheumatoid arthritis rheumatoid arthritis Chronic, progressive autoimmune disease causing connective-tissue inflammation, mostly in synovial joints. It can occur at any age, is more common in women, and has an unpredictable course. (RA) only if there is no indication of improvement when conventional treatment therapies such as nonsteroidal anti-inflammatory agents and other anti-rheumatic agents are used, on July 21. Tanabe has already marketed Remicade, an anti-human TNF-alpha monoclonal antibody drug that has shown high efficacy in treating over 10,000 patients. When used in combination with Methotrexate, Remicade achieves the maximum clinical effect by stopping joint destruction. Tanabe speculates that the launch of Methotrexate will accelerate the use of Remicade in the future. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion